ArticleBMC infectious diseases2025
Clinico-epidemiological and immunological characteristics of rickettsioses in a Sri Lankan patient cohort 2018-2023.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRickettsioses, caused by intracellular bacteria of the genera Rickettsia and Orientia, are transmitted to humans through arthropod vectors such as ticks, fleas, and mites. Over the past two decades, this disease has been recognized as a significant cause of acute febrile illness in Sri Lanka. However, only a limited number of studies have focused on clinico-epidemiological characteristics of patients and immunological diagnostic approaches for disease confirmation.
methodA cross-sectional study was conducted at the Rickettsial Disease Diagnostic and Research Laboratory (RDDRL), University of Kelaniya, Sri Lanka, from 2018 to 2023 from the clinically suspected patients referred for disease confirmation. Clinical, demographic, epidemiological, biochemical, and laboratory data were collected via a questionnaire by reviewing the archived records. The serological finding of the immunofluorescence assay (IFA) conducted for patients samples were retrieved. The patients who were positive for IFA-IgG (> 1:128 as per presumptive confirmation of acute rickettsial illness) were taken as the test group and the negative group was taken as the control group. Data were analyzed using chi-square tests followed by a Correlation analysis between the variables using Pearson correlation.
resultsOut of 1,221 cases, 249 (20.4%) were serologically "confirmed" as positive for rickettsial infection. The test group consisted predominantly of males, similar to the control group. Most cases were males and < 9 years of age followed by 10-19 years. Among the age groups, 10-19 years and 50-59 years, categories indicated a significant positive relationship according to the chi-squared statistics (P < 0.05). A seasonal trend was observed, with higher case numbers reported from January to February. Laboratory findings indicated significant differences between test and control groups in leucopenia (P = 0.005, χ²=7.87), increased neutrophil count (P = 0.0004, χ²=12.71), elevated alanine aminotransferase (P = 0.0001, χ²=14.64), elevated aspartate aminotransferase (P = 0.0001, χ²=18.24), urine occult blood (P = 0.024, χ²=5.09), and raised erythrocyte sedimentation rate (P = 0.034, χ²=4.51). Clinical manifestations showed no major deviations. Notably, eschar was more prevalent in O. tsutsugamushi cases (33.3%) compared to SFG rickettsioses (13.3%).
conclusionThis study highlights the need for improved awareness, diagnostic facilities, and vector control measures to manage rickettsial infections effectively in Sri Lanka. Understanding epidemiological patterns and clinical manifestations is crucial for developing effective surveillance and prevention strategies. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.